Jazz Pharmaceuticals plc (JAZZ)

NASDAQ: JAZZ · Real-Time Price · USD

186.95

-1.32 (-0.70%)

At close: Apr 2, 2026, 4:00 PM EDT

187.25

+0.30 (0.16%)

After-hours: Apr 2, 2026, 4:53 PM EDT

Jazz Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	4,268	4,069	3,834
Revenue Growth (YoY)	4.88%	6.12%	-
Cost of Revenue	503.3	445.71	435.58
Gross Profit	3,764	3,623	3,399
Selling, General & Admin	1,809	1,385	1,343
Depreciation & Amortization Expenses	654.66	627.31	608.28
Research & Development	1,731	894	868.66
Total Operating Expenses	4,195	2,907	2,820
Operating Income	-430.24	716.63	578.58
Total Non-Operating Income (Expense)	-197.62	-246.28	-280.65
Pretax Income	-627.86	470.35	297.93
Provision for Income Taxes	-272.44	-91.43	-119.91
Net Income	-356.15	560.12	414.83
Net Income to Common	-356.15	560.12	414.83
Net Income Growth	-	35.02%	-
Shares Outstanding (Basic)	61	62	63
Shares Outstanding (Diluted)	61	66	72
Shares Change (YoY)	-7.61%	-8.41%	-
EPS (Basic)	-5.84	9.06	6.55
EPS (Diluted)	-5.84	8.65	6.10
EPS Growth	-	41.80%	-
Shares Outstanding	61.44	60.63	62.26
Free Cash Flow	1,297	1,358	1,068
Free Cash Flow Growth	-4.48%	27.13%	-
Free Cash Flow Per Share	21.27	20.57	14.82
Gross Margin	88.21%	89.05%	88.64%
Operating Margin	-10.08%	17.61%	15.09%
Profit Margin	-8.35%	13.77%	10.82%
FCF Margin	30.39%	33.37%	27.86%
EBITDA	266.06	1,377	1,217
EBITDA Margin	6.23%	33.83%	31.75%
EBIT	-430.24	716.63	578.58
EBIT Margin	-10.08%	17.61%	15.09%
Effective Tax Rate	43.39%	-19.44%	-40.25%

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q